Who Paid My Doc
Ravi Kapadia
Surgery Bakersfield, CA Medical Doctor
NPI 1669736427 CMS profile 809127
5500 Ming Ave Ste 320, Bakersfield, CA 93309
General payments
$73,044
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Ravi Kapadia of Bakersfield, CA is reported in the CMS Open Payments database as having received $73,044 across 228 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $541 | 5 | |
| 2024 | General | $29,753 | 45 | |
| 2023 | General | $34,168 | 100 | |
| 2022 | General | $607 | 16 | |
| 2021 | General | $368 | 8 | |
| 2020 | General | $5,392 | 33 | |
| 2019 | General | $2,214 | 21 |
Beside peers
- Ravi Kapadia
- Surgery median
- Middle half of Surgery
- National median
In program year 2025, general payments to Ravi Kapadia were reported at $541. Among 17,702 Surgery profiles paid that year, the median was $280 and the middle half received between $91 and $1,259.
Show as a table
| Year | Ravi Kapadia | Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $2,214 | $253 | $82–$1,521 | $163 |
| 2020 | $5,392 | $131 | $40–$706 | $114 |
| 2021 | $368 | $168 | $50–$904 | $132 |
| 2022 | $607 | $224 | $76–$1,218 | $149 |
| 2023 | $34,168 | $253 | $82–$1,255 | $160 |
| 2024 | $29,753 | $279 | $90–$1,381 | $164 |
| 2025 | $541 | $280 | $91–$1,259 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 50 billing codesPaid by Medicare
$77,336,541
Medicare patients
113
Services billed
64,895
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 70% | |
| Arthritis | 50% | |
| Heart failure | 45% | |
| Chronic kidney disease | 43% | |
| Depression | 43% | |
| Ischemic heart disease | 41% | |
| COPD | 35% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Helicoll, per square centimeter Q4164 | Office | 28 | 55,394 | $68,930,106 |
| Derm-maxx, per square centimeter Q4238 | Office | 11 | 3,430 | $4,234,515 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
228 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Surgery in California
Related records
Surgery in California
Practitioners in the same specialty and state, ranked by reported value.
All Surgery
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.